This report presents an analysis of antibacterial agents in preclinical (third annual review) and clinical (fifth annual review) development. The analysis covers traditional (direct-acting small molecules) and non-traditional antibacterial agents in development worldwide. It evaluates to what extent... the present pipeline addresses infections caused by WHO Priority Pathogens, Mycobacterium tuberculosis and Clostridioides difficile. The report also provides an assessment of the traditional agents with respect to whether they meet a set of predefined criteria for innovation, namely absence of known cross-resistance, new target, mode of action and/or class. It also includes an overview of the agents that obtained authorization since 1 July 2017.
more
Resumo: o que é esta orientação dinâmica?
Pergunta clínica: qual é o papel dos medicamentos na prevenção da COVID-19?
Público-alvo: o público-alvo são os médicos e os tomadores de decisão na área da saúde.
Prática atual: o uso atual de medicamentos para prevenção da COVID-19 é ...variável, refletindo uma incerteza em grande escala. Numerosos estudos clínicos randomizados de muitos medicamentos estão em andamento para orientar melhor a prática. Esta primeira versão de Medicamentos para prevenção da COVID-19: Orientação dinâmica da OMS contém novas
informações e uma recomendação sobre a hidroxicloroquina. (1) Segue-se a publicação de seis estudos sintetizados em uma meta-análise dinâmica de rede (NMA).
more
National Tuberculosis and Leprosy Conrol Programme
Road safety is an issue that does not receive anywhere near the attention it deserves – and it really is one
of our great opportunities to save lives around the world
La presente Nota Informativa sirve como orientación a los solicitantes que están preparando una solicitud de financiamiento del Fondo Mundial para la tuberculosis. Ofrece recomendaciones sobre cómo establecer prioridades y metas para que las intervenciones relacionadas con la tuberculosis consiga...n la máxima repercusión posible. Promueve inversiones estratégicas para salvar vidas y obtener beneficios económicos, teniendo en cuenta la situación de la tuberculosis en cada país y otros factores contextuales:
• Su perfil de tuberculosis: tanto farmacosensible como farmacorresistente.
• El contexto del sistema de salud del país.
• Los obstáculos relacionados con los derechos humanos y el género.
• Las barreras socioeconómicas y estructurales que impiden acceder a los servicios
de tuberculosis.
more
Full eHandbook under: http://www.msh.org/resources/health-systems-in-action-an-ehandbook-for-leaders-and-managers
Effective supply management has the potential to make a powerful contribution to the reliable availability of essential medicines, which are a crucial part of the delivery of highqualit...y health care services. Because medicines are costly and poor management so often results in waste, good supply management is also crucial to the cost-effectiveness of providing medicines.
more
INT J TUBERC LUNG DIS 22(2):197–205 http://dx.doi.org/10.5588/ijtld.17.0245
Prices people pay for medicines.
Licensed pharmaceutical products (marketing authorization) should be manufactured only by licensed manufacturers (holders of a manufacturing authorization) whose activities are regularly inspected by competent national authorities. This guide to GMP shall be used as a standard to justify GMP status,... which constitutes one of the elements of the WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce, through the assessment of applications for manufacturing authorizations and as a basis for the inspection of manufacturing facilities. It may also be used as training material for government medicines inspectors, as well as for production, QC and QA personnel in the industry
more
L'objectif de la cartographie est d'obtenir une vision claire et précise des systèmes et politiques d'approvisionnement, de distribution et de financement des produits pharmaceutiques existants au Burkina Faso et de déterminer leur pertinence, leur cohérence et leurs forces et faiblesses en term...es d’efficacité, d’efficience, de durabilité et d’impact à long terme au regard des normes et recommandations nationales, régionales et internationales relatives à la règlementation et aux bonnes pratiques pharmaceutiques et à l'efficacité de l'aide.
more